{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/giant-cell-arteritis/","result":{"data":{"firstChapter":{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 49d726fd-1045-41c4-a40f-9d25746fd6c0 --><h1>Giant cell arteritis: Summary</h1><!-- end field 49d726fd-1045-41c4-a40f-9d25746fd6c0 -->","htmlStringContent":"<!-- begin item 273f2221-a142-42d7-b012-0cf58e97e5ae --><!-- begin field 721d305f-74b0-4b7f-b134-8c97dc539154 --><ul><li class=\"MsoNormal\">Giant cell arteritis (GCA) is a chronic vasculitis characterized by granulomatous inflammation in the walls of medium and large arteries. It usually affects people over 50 years of age.</li><li>In the UK population, incidence is about 2.2 per 10,000 person years.</li><li>Complications of GCA are largely prevented by treatment with adequate doses of corticosteroids and include:<ul><li>Vision loss.</li><li>Large artery complications (such as aortic aneurysm, aortic dissection, and large artery stenosis).</li><li>Cardiovascular disease (such as stroke).</li></ul></li><li>Relapses are common and occur in up to 50% of cases.</li><li>GCA should be suspected if the person is aged 50 years or older and has:<ul><li>A new-onset headache that is usually unilateral in the temporal area, and/or</li><li>A temporal artery abnormality such as tenderness, thickening, or nodularity.</li></ul></li><li>Other symptoms and signs of GCA include:<ul><li>Visual disturbances such as vision loss or diplopia.</li><li>Scalp tenderness.</li><li>Intermittent jaw claudication.</li><li>Systemic features such as fever, fatigue, anorexia, weight loss, and depression.</li><li>Features of polymyalgia rheumatica.</li><li>Neurological features (for example stroke).</li><li>Bruits, blood pressure difference between arms, or intermittent limb claudication.</li></ul></li><li>GCA is a medical emergency.</li><li>If the person has new visual loss or diplopia an urgent (same day) assessment by an ophthalmologist should be arranged.<ul><li>Depending on the clinical situation, the specialist may advise one-off high dose corticosteroid treatment in primary care while the person awaits transfer to ophthalmology.</li></ul></li><li>All other people with suspected GCA should be discussed urgently with a specialist and referred to secondary care using a local fast track GCA pathway.<ul><li>Specialist evaluation (usually by a rheumatologist) should take place on the same working day if possible, and in all cases within 3 working days.</li><li>Depending on the clinical situation, initiation of glucocorticoid treatment in primary care may be advised — the standard initial dose for GCA without visual symptoms is 40–60 mg oral prednisolone per day.</li><li>Blood tests (such as full blood count, erythrocyte sedimentation rate, and C-reactive protein) should be considered but referral must not be delayed while awaiting results.</li></ul></li><li>Once the diagnosis has been confirmed in secondary care:<ul><li>Assessment of prognostic factors and comorbidities relevant to treatment (such as infection, diabetes, hypertension, glaucoma, peptic ulcer, and bone fracture risk) and consideration of preventative measures (such as bone and/or gastrointestinal protection) should take place.</li><li>Initial doses of glucocorticoids should be continued until GCA symptoms and inflammatory markers resolve. Once in clinical remission, the specialist will determine tapering schedules — treatment duration is usually 1–2 years.</li><li>Regular review should be arranged to monitor for disease relapse and steroid-related adverse effects.</li></ul></li><li>If relapse occurs, urgent advice should be sought from the person’s specialist regarding further management.<ul><li>Depending on the clinical situation an increase in corticosteroid or addition of adjunctive treatment may be indicated.</li><li>Relapse with new-onset visual disturbance requires urgent (same day) assessment by ophthalmology.</li></ul></li></ul><!-- end field 721d305f-74b0-4b7f-b134-8c97dc539154 --><!-- end item 273f2221-a142-42d7-b012-0cf58e97e5ae -->","topic":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90","topicId":"922f2e2a-90b2-4d8e-8df9-97f686e2dd9c","topicName":"Giant cell arteritis","slug":"giant-cell-arteritis","aliases":[],"chapters":[{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"9ffc44fb-e6ab-5564-afaf-41f6ec23ae59","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes"},{"id":"b6663d8f-4d43-5493-b6ea-21be0eeae0f0","slug":"update","fullItemName":"Update"}]},{"id":"fbf9fbe8-db19-571e-9da9-58c8a33c3a25","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"4a198ad6-17e2-5c80-a074-90f34f9ef1b7","slug":"goals","fullItemName":"Goals"},{"id":"a77ffdda-deba-58f0-9fec-65219eeb836f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0979f67-3177-527b-add9-89f384b45f07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c79d9855-b433-5fba-b27d-0999158ea93d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"941fce5c-cd66-5a8b-94ed-bcdf176a7c54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e4b575e0-3a70-5c29-afb2-b56f7ba46307","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ea4258e9-d463-5d81-ac84-d12cda80042f","slug":"definition","fullItemName":"Definition"},{"id":"cfe98d94-f2b6-58e5-828a-449fb49d3b2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications"},{"id":"0c5a3725-06fd-5f2f-8aae-4f12da09ec7d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis"},{"id":"e8c3752d-f9fb-5624-a000-60653edb83ac","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","slug":"management","fullItemName":"Management","subChapters":[{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"}]},{"id":"5a8fb527-3c07-5253-86eb-d10fc0d5b656","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ff1b1a4d-96ab-5f26-82ea-b4b059ac602f","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"627bf4b4-8b65-59ac-8e48-1f7ac20afa3c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"403ae553-2865-56af-9e95-a012c674b4de","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17c8d522-4e76-5f45-aa32-83ed694272f1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bb85fa5d-a667-5361-b411-a3837f26bdc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1f292226-0f24-56c9-983b-c8fa1738c13f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e1a018ae-4d22-516e-8a99-d688c0d3dda6","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90","topicId":"922f2e2a-90b2-4d8e-8df9-97f686e2dd9c","topicName":"Giant cell arteritis","slug":"giant-cell-arteritis","aliases":[],"topicSummary":"Giant cell arteritis is a type of chronic vasculitis characterized by granulomatous inflammation in the walls of medium and large arteries.","lastRevised":"Last revised in September 2020","nextPlannedReviewBy":"2025-09-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-08","nextPlannedReviewByDisplay":"August 2025","specialities":[{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"},{"id":"f8332083-731e-50fe-a895-030315ce6083","name":"Musculoskeletal","slug":"musculoskeletal"},{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"485bdd1b-4437-5374-838e-f1f1db61a424","name":"Eyes","slug":"eyes"}],"chapters":[{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"9ffc44fb-e6ab-5564-afaf-41f6ec23ae59","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes"},{"id":"b6663d8f-4d43-5493-b6ea-21be0eeae0f0","slug":"update","fullItemName":"Update"}]},{"id":"fbf9fbe8-db19-571e-9da9-58c8a33c3a25","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"4a198ad6-17e2-5c80-a074-90f34f9ef1b7","slug":"goals","fullItemName":"Goals"},{"id":"a77ffdda-deba-58f0-9fec-65219eeb836f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0979f67-3177-527b-add9-89f384b45f07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c79d9855-b433-5fba-b27d-0999158ea93d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"941fce5c-cd66-5a8b-94ed-bcdf176a7c54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e4b575e0-3a70-5c29-afb2-b56f7ba46307","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"ea4258e9-d463-5d81-ac84-d12cda80042f","slug":"definition","fullItemName":"Definition"},{"id":"cfe98d94-f2b6-58e5-828a-449fb49d3b2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications"},{"id":"0c5a3725-06fd-5f2f-8aae-4f12da09ec7d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis"},{"id":"e8c3752d-f9fb-5624-a000-60653edb83ac","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","slug":"management","fullItemName":"Management","subChapters":[{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"}]},{"id":"5a8fb527-3c07-5253-86eb-d10fc0d5b656","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ff1b1a4d-96ab-5f26-82ea-b4b059ac602f","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"627bf4b4-8b65-59ac-8e48-1f7ac20afa3c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"403ae553-2865-56af-9e95-a012c674b4de","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17c8d522-4e76-5f45-aa32-83ed694272f1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bb85fa5d-a667-5361-b411-a3837f26bdc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1f292226-0f24-56c9-983b-c8fa1738c13f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e1a018ae-4d22-516e-8a99-d688c0d3dda6","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90"}},"staticQueryHashes":["3666801979"]}